Adaptive Historical Balance Sheet

ADPT Stock

USD 7.86 0.15 1.95%

Trend analysis of Adaptive Biotechnologies Corp balance sheet accounts such as Other Current Liab of 16.8 M, Total Current Liabilities of 84.7 M or Total Stockholder Equity of 347 M provides information on Adaptive Biotechnologies' total assets, liabilities, and equity, which is the actual value of Adaptive Biotechnologies to its prevalent stockholders. By breaking down trends over time using Adaptive Biotechnologies balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Adaptive Biotechnologies latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Adaptive Biotechnologies is a good buy for the upcoming year.

Adaptive Biotechnologies Inventory

13.19 Million

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adaptive Biotechnologies Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

About Adaptive Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Adaptive Biotechnologies at a specified time, usually calculated after every quarter, six months, or one year. Adaptive Biotechnologies Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Adaptive Biotechnologies and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Adaptive currently owns. An asset can also be divided into two categories, current and non-current.

Adaptive Biotechnologies Balance Sheet Chart

At this time, Adaptive Biotechnologies' Short Term Investments are comparatively stable compared to the past year. Long Term Debt Total is likely to gain to about 44.2 M in 2025, whereas Total Stockholder Equity is likely to drop slightly above 347 M in 2025.

Total Assets Other Current Liab Total Current Liabilities Other Liab

Add Fundamental

Total Assets

Total assets refers to the total amount of Adaptive Biotechnologies assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Adaptive Biotechnologies books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Adaptive Biotechnologies balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Adaptive Biotechnologies Corp are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from Adaptive Biotechnologies' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Adaptive Biotechnologies current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adaptive Biotechnologies Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

	2022	2023	2024	2025 (projected)
Other Current Liabilities	18.9M	22.2M	25.6M	16.8M
Total Assets	856.6M	661.1M	760.3M	811.6M

Other Current Liab Total Assets

Adaptive Biotechnologies balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Net Receivables	Good Will	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Long Term Debt Total	Non Current Liabilities Total	Capital Surpluse	Inventory
Total Assets		0.84	0.95	0.99	0.87	0.98	0.89	0.98	0.52	-0.65	0.6	0.63	0.9	0.69	0.49	-0.4	0.96	0.58	-0.29	0.92	0.46	0.93	0.93	-0.94	0.89	0.85
Other Current Liab	0.84		0.95	0.87	0.89	0.92	0.94	0.89	0.81	-0.91	0.86	0.27	0.78	0.89	0.24	-0.51	0.75	0.82	-0.39	0.97	0.79	0.76	0.94	-0.94	0.98	0.96
Total Current Liabilities	0.95	0.95		0.96	0.9	0.97	0.98	0.98	0.67	-0.83	0.77	0.5	0.9	0.82	0.35	-0.45	0.85	0.75	-0.33	0.98	0.68	0.84	0.96	-0.98	0.98	0.96
Total Stockholder Equity	0.99	0.87	0.96		0.9	0.99	0.9	0.99	0.54	-0.69	0.64	0.6	0.91	0.72	0.51	-0.38	0.94	0.6	-0.26	0.95	0.48	0.92	0.94	-0.96	0.92	0.87
Other Liab	0.87	0.89	0.9	0.9		0.93	0.81	0.87	0.69	-0.78	0.86	0.23	0.68	0.83	0.61	-0.43	0.87	0.75	-0.32	0.95	0.48	0.9	0.94	-0.93	0.93	0.8
Net Tangible Assets	0.98	0.92	0.97	0.99	0.93		0.92	0.98	0.62	-0.75	0.72	0.52	0.89	0.77	0.48	-0.39	0.91	0.66	-0.27	0.98	0.55	0.9	0.96	-0.98	0.96	0.9
Property Plant And Equipment Net	0.89	0.94	0.98	0.9	0.81	0.92		0.94	0.67	-0.85	0.76	0.49	0.89	0.79	0.17	-0.43	0.76	0.76	-0.31	0.95	0.78	0.74	0.92	-0.94	0.96	0.98
Current Deferred Revenue	0.98	0.89	0.98	0.99	0.87	0.98	0.94		0.57	-0.73	0.65	0.63	0.95	0.74	0.44	-0.41	0.88	0.64	-0.29	0.95	0.55	0.86	0.95	-0.97	0.93	0.92
Net Debt	0.52	0.81	0.67	0.54	0.69	0.62	0.67	0.57		-0.93	0.82	-0.06	0.44	0.97	0.1	-0.81	0.46	0.93	-0.75	0.72	0.75	0.49	0.78	-0.71	0.74	0.72
Retained Earnings	-0.65	-0.91	-0.83	-0.69	-0.78	-0.75	-0.85	-0.73	-0.93		-0.91	-0.09	-0.6	-0.96	-0.11	0.63	-0.55	-0.96	0.54	-0.85	-0.83	-0.57	-0.86	0.83	-0.88	-0.86
Accounts Payable	0.6	0.86	0.77	0.64	0.86	0.72	0.76	0.65	0.82	-0.91		-0.09	0.44	0.88	0.27	-0.47	0.57	0.91	-0.38	0.83	0.71	0.61	0.8	-0.77	0.86	0.75
Cash	0.63	0.27	0.5	0.6	0.23	0.52	0.49	0.63	-0.06	-0.09	-0.09		0.77	0.11	0.15	-0.1	0.52	0.01	-0.08	0.4	0.13	0.42	0.41	-0.47	0.36	0.43
Non Current Assets Total	0.9	0.78	0.9	0.91	0.68	0.89	0.89	0.95	0.44	-0.6	0.44	0.77		0.6	0.3	-0.36	0.74	0.49	-0.26	0.84	0.51	0.69	0.83	-0.89	0.82	0.89
Non Currrent Assets Other	0.69	0.89	0.82	0.72	0.83	0.77	0.79	0.74	0.97	-0.96	0.88	0.11	0.6		0.28	-0.78	0.63	0.96	-0.7	0.85	0.72	0.65	0.91	-0.85	0.86	0.82
Other Assets	0.49	0.24	0.35	0.51	0.61	0.48	0.17	0.44	0.1	-0.11	0.27	0.15	0.3	0.28		-0.13	0.57	0.16	-0.06	0.41	-0.37	0.58	0.46	-0.47	0.34	0.18
Long Term Debt	-0.4	-0.51	-0.45	-0.38	-0.43	-0.39	-0.43	-0.41	-0.81	0.63	-0.47	-0.1	-0.36	-0.78	-0.13		-0.36	-0.74	0.99	-0.45	-0.47	-0.37	-0.61	0.5	-0.45	-0.48
Cash And Short Term Investments	0.96	0.75	0.85	0.94	0.87	0.91	0.76	0.88	0.46	-0.55	0.57	0.52	0.74	0.63	0.57	-0.36		0.51	-0.26	0.85	0.31	0.99	0.86	-0.85	0.81	0.69
Net Receivables	0.58	0.82	0.75	0.6	0.75	0.66	0.76	0.64	0.93	-0.96	0.91	0.01	0.49	0.96	0.16	-0.74	0.51		-0.67	0.77	0.76	0.54	0.82	-0.76	0.8	0.75
Good Will	-0.29	-0.39	-0.33	-0.26	-0.32	-0.27	-0.31	-0.29	-0.75	0.54	-0.38	-0.08	-0.26	-0.7	-0.06	0.99	-0.26	-0.67		-0.33	-0.41	-0.26	-0.5	0.39	-0.32	-0.36
Common Stock Total Equity	0.92	0.97	0.98	0.95	0.95	0.98	0.95	0.95	0.72	-0.85	0.83	0.4	0.84	0.85	0.41	-0.45	0.85	0.77	-0.33		0.66	0.85	0.97	-0.99	1.0	0.94
Common Stock Shares Outstanding	0.46	0.79	0.68	0.48	0.48	0.55	0.78	0.55	0.75	-0.83	0.71	0.13	0.51	0.72	-0.37	-0.47	0.31	0.76	-0.41	0.66		0.32	0.61	-0.6	0.72	0.78
Short Term Investments	0.93	0.76	0.84	0.92	0.9	0.9	0.74	0.86	0.49	-0.57	0.61	0.42	0.69	0.65	0.58	-0.37	0.99	0.54	-0.26	0.85	0.32		0.86	-0.84	0.81	0.68
Long Term Debt Total	0.93	0.94	0.96	0.94	0.94	0.96	0.92	0.95	0.78	-0.86	0.8	0.41	0.83	0.91	0.46	-0.61	0.86	0.82	-0.5	0.97	0.61	0.86		-0.99	0.96	0.91
Non Current Liabilities Total	-0.94	-0.94	-0.98	-0.96	-0.93	-0.98	-0.94	-0.97	-0.71	0.83	-0.77	-0.47	-0.89	-0.85	-0.47	0.5	-0.85	-0.76	0.39	-0.99	-0.6	-0.84	-0.99		-0.97	-0.94
Capital Surpluse	0.89	0.98	0.98	0.92	0.93	0.96	0.96	0.93	0.74	-0.88	0.86	0.36	0.82	0.86	0.34	-0.45	0.81	0.8	-0.32	1.0	0.72	0.81	0.96	-0.97		0.95
Inventory	0.85	0.96	0.96	0.87	0.8	0.9	0.98	0.92	0.72	-0.86	0.75	0.43	0.89	0.82	0.18	-0.48	0.69	0.75	-0.36	0.94	0.78	0.68	0.91	-0.94	0.95

Click cells to compare fundamentals

Adaptive Biotechnologies Account Relationship Matchups

Adaptive Biotechnologies balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	1.1B	923.3M	856.6M	661.1M	760.3M	811.6M
Other Current Liab	19.8M	19.5M	18.9M	22.2M	25.6M	16.8M
Total Current Liabilities	105.2M	113.8M	109.8M	88.0M	101.2M	84.7M
Total Stockholder Equity	743.3M	604.0M	464.2M	308.4M	354.7M	347.0M
Other Liab	226.3M	163.6M	98.8M	184.0M	211.6M	125.4M
Net Tangible Assets	440.1M	614.1M	476.5M	338.4M	389.1M	205.2M
Property Plant And Equipment Net	139.0M	172.9M	164.2M	120.3M	138.4M	108.4M
Current Deferred Revenue	73.3M	80.5M	64.1M	48.6M	55.9M	55.7M
Net Debt	(15.6M)	(27.3M)	18.0M	164.4M	189.0M	198.5M
Retained Earnings	(511.6M)	(718.9M)	(919.1M)	(1.1B)	(1.0B)	(978.4M)
Accounts Payable	3.2M	3.3M	8.1M	7.7M	8.9M	4.8M
Cash	123.4M	139.1M	90.0M	65.1M	74.8M	102.9M
Non Current Assets Total	389.5M	520.6M	294.5M	250.9M	288.6M	324.4M
Non Currrent Assets Other	2.7M	3.0M	4.5M	6.5M	7.5M	7.9M
Other Assets	39.5M	2.7M	3.0M	4.5M	4.0M	6.7M
Cash And Short Term Investments	688.3M	353.1M	498.2M	346.4M	398.4M	443.1M
Net Receivables	10.0M	17.4M	40.1M	38.0M	43.7M	45.8M
Common Stock Shares Outstanding	131.2M	140.4M	142.5M	144.4M	166.0M	131.8M
Short Term Investments	564.8M	214.0M	408.2M	281.3M	323.5M	340.3M
Liabilities And Stockholders Equity	1.1B	923.3M	856.6M	661.1M	760.3M	811.6M
Non Current Liabilities Total	268.0M	205.4M	282.7M	264.8M	238.4M	276.3M
Capital Surpluse	935.8M	1.3B	1.3B	1.4B	1.6B	910.1M
Inventory	14.1M	19.3M	14.5M	14.4M	16.6M	13.2M
Other Current Assets	14.5M	13.0M	9.4M	11.4M	13.1M	10.7M
Other Stockholder Equity	1.3B	1.3B	1.4B	1.5B	1.7B	865.0M
Total Liab	373.1M	319.2M	392.5M	352.9M	317.6M	337.9M
Net Invested Capital	743.3M	604.0M	464.2M	308.4M	354.7M	347.0M
Property Plant And Equipment Gross	139.0M	172.9M	164.2M	193.6M	222.6M	119.9M
Total Current Assets	726.9M	402.7M	562.1M	410.2M	471.7M	487.2M
Accumulated Other Comprehensive Income	893K	(1.1M)	(4.1M)	215K	193.5K	203.2K
Non Current Liabilities Other	268.0M	205.4M	125.4M	130.7M	150.3M	133.7M
Net Working Capital	621.7M	288.9M	452.4M	322.2M	370.5M	402.6M
Intangible Assets	10.2M	8.5M	6.8M	5.1M	4.6M	8.2M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Adaptive Stock Analysis

When running Adaptive Biotechnologies' price analysis, check to measure Adaptive Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptive Biotechnologies is operating at the current time. Most of Adaptive Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Adaptive Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptive Biotechnologies' price. Additionally, you may evaluate how the addition of Adaptive Biotechnologies to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Adaptive Historical Balance Sheet

Adaptive Biotechnologies Inventory

13.19 Million

About Adaptive Balance Sheet Analysis

Adaptive Biotechnologies Balance Sheet Chart

Total Assets

Total Current Liabilities

Adaptive Biotechnologies balance sheet Correlations

Adaptive Biotechnologies Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Adaptive Biotechnologies balance sheet Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Adaptive Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Capital Surpluse	+ 1.0	Common Stock Total Equity
Total Stockholder Equity	+ 0.99	Total Assets
Net Tangible Assets	+ 0.99	Total Stockholder Equity
Current Deferred Revenue	+ 0.99	Total Stockholder Equity
Good Will	+ 0.99	Long Term Debt
Short Term Investments	+ 0.99	Cash And Short Term Investments

Non Current Liabilities Total	- 0.99	Long Term Debt Total
Non Current Liabilities Total	- 0.99	Common Stock Total Equity
Non Current Liabilities Total	- 0.98	Net Tangible Assets
Non Current Liabilities Total	- 0.98	Total Current Liabilities
Capital Surpluse	- 0.97	Non Current Liabilities Total
Non Current Liabilities Total	- 0.97	Current Deferred Revenue